✨ Free AI Report
MEI Pharma, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview MEI Pharma, Inc.
Research Preview

MEI Pharma, Inc.: Business Overview, Financials & Competitive Analysis

MEI Pharma is a clinical-stage oncology company that historically developed innovative cancer therapies. However, as of September 2025, the company rebranded to Lite Strategy, Inc. and pivoted to digital asset treasur...

Analyst-debate audio for MEI Pharma, Inc.

AskCyborg analysts argue the bull and bear cases for MEI Pharma, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
MEI Pharma, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
3/ 10Challenged

Cyborg Score thesis

High-risk micro-cap transitioning from oncology to crypto treasury with uncertain pathway to...

Read the full analyst-debate transcript →
Industry Clinical-stage oncology therapeutics
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: June 22, 2026
AI-Verified Research
30+ Page Report

Get the Latest MEI Pharma, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

MEI Pharma, Inc. Overview

Pro stress-test →

MEI Pharma is a clinical-stage oncology company that historically developed innovative cancer therapies. However, as of September 2025, the company rebranded to Lite Strategy, Inc. and pivoted to digital asset treasury management, acquiring Litecoin holdings while maintaining its oncology pipeline.

Strategic Profile

Pro stress-test →

Originally focused on novel cancer therapies including CDK9 and mitochondrial pathway inhibitors, MEI Pharma underwent a strategic transformation in 2025. The company now emphasizes crypto treasury strategy with guidance from Litecoin creator Charlie Lee while evaluating continued development of voruciclib and zandelisib.

Competitive Landscape

Pro stress-test →

As a transitional entity, MEI Pharma's competitive position is ambiguous. Historically it competed in oncology against companies like Agios Pharmaceuticals and Forma Therapeutics in targeted cancer therapies. Post-rebranding, it now competes in crypto treasury management, a nascent corporate strategy space.

Industry Context

MEI Pharma, Inc. operates in Clinical-stage oncology therapeutics.

Key facts

Founded: 2005 · Headquarters: San Diego, US · Employees: N/A · Revenue: N/A · Market cap: $100.8M

What the analysts stress-tested

The top findings that survived the multi-agent debate for MEI Pharma, Inc..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when MEI Pharma, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Oncology Pipeline Competitors (Historical)Metabolic and cancer therapeutics→Targeted Cancer TherapiesEpigenetic cancer drug development→

Compare MEI Pharma, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

MEI Pharma, Inc. operates in Clinical-stage oncology therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Clinical-stage oncology therapeutics research →
NEW · MCP server

Ask your AI assistant about MEI Pharma, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare MEI Pharma, Inc. and its top competitor on Cyborg Score”
“What did MEI Pharma, Inc. do this quarter?”
“Is MEI Pharma, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does MEI Pharma, Inc. do?+
MEI Pharma is a clinical-stage oncology company that historically developed innovative cancer therapies. However, as of September 2025, the company rebranded to Lite Strategy, Inc. and pivoted to digital asset treasur...
What is MEI Pharma, Inc.'s Cyborg Score?+
MEI Pharma, Inc. has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are MEI Pharma, Inc.'s main competitors?+
Named competitors include Oncology Pipeline Competitors (Historical), Targeted Cancer Therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full MEI Pharma, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the MEI Pharma, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track MEI Pharma, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

Other strong performers across the analyst-debate framework. Click any to see their research report.

9Anthropic9Dubai Electricity and Water Authority (DEWA)9Emaar Development PJSC9Gold Fields Limited9Western Digital Corporation9Advantest Corporation9Fast Retailing Co., Ltd.9JPMorgan Chase & Co.9Siemens AG9Space Exploration Technologies Corp8Arcellx, Inc.8Gentili Mosconi S.p.A.8Neurogene Inc.8Selvaag Bolig ASA8Satellogic Inc.8Klaveness Combination Carriers ASA8Unusual Machines, Inc.8Shoei Co., Ltd.